AstraZeneca to Pay $1.2 Billion Upfront to CSPC Pharmaceuticals to Expand Weight Management Portfolio
I'm PortAI, I can summarize articles.
AstraZeneca will pay $1.2 billion to CSPC Pharmaceuticals to enhance its weight management portfolio, focusing on therapies for obesity and type 2 diabetes. CSPC could earn up to $3.5 billion in development and regulatory milestones. The deal includes exclusive global rights outside China for CSPC's once-monthly injectable weight-management products and options for future metabolic programs. The transaction is expected to close in Q2.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments